Therapeutic Workshop Details
CNS: Alzheimer's Disease - Novel Mechanisms and Targets Renewing the Future for Patients
Wednesday, October 10, 2007
9:10 AM
Twin Peaks South
Alzheimer's disease now afflicts some 4.5 million Americans, a number expected to increase to 16 million by 2050. The cost to treat victims has already hit $100 billion a year, ranking behind only heart disease and cancer. Many new medicines and molecules in development for AD are moving from the lab to the clinic, addressing novel targets, the underlying mechanisms of disease and its pathology. Hear from about the disease-modifying drugs in development that have the potential to redefine the impact of Alzheimer's disease.
Moderators
- Elemer Piros, PhD; Senior Biotechnology Analyst, Acumen BioFin, a Division of Rodman & Renshaw, LLC
Panelists
- Adam Boxer, MD, PhD; Assistant Professor of Neurology; Alzheimer's Disease Research Center, University of California, San Francisco, Vera and John Graziadio Scholar in Alzheimer?s Disease Research,
- Lauren C. Costantini, PhD; Vice President Clinical Development, Accera, Inc.
- J. Donald deBethizy, Ph.D.; President and Chief Executive Officer, Targacept, Inc.
- W. Scott Harkonen, MD; President and Chief Executive Officer, CoMentis, Inc.
- David T. Hung, MD; President and Chief Executive Officer, Medivation, Inc.
Who's Who
Elemer Piros is a Senior Biotechnology Analyst at Rodman & Renshaw. Prior to joining Rodman, Dr. Piros was a buyside biotechnology analyst at Spear, Leeds & Kellogg, now a wholly owned subsidiary of Goldman Sachs. From 1990 to 2000, Dr. Piros conducted academic research in the field of neuroscience focusing on understanding the molecular mechanism of communication in the nervous system. Dr. Piros earned degrees in mathematics and in biology and a Ph.D. in neuroscience at the University of California at Los Angeles. He then completed post-doctoral training at Cornell University Medical College in New York. Dr. Piros has been ranked # 1 among biotechnology analysts in The Wall Street Journal?s annual 'Best on the Street' survey in 2007. Currently, Dr. Piros? research universe includes emerging biotechnology companies that develop products addressing the nervous system and cancer.